Washington, DC — November 8, 2025 — Leads & Copy — MMJ International Holdings is positioned to deliver safe, pharmaceutical-grade cannabis treatments as President Trump signals openness to marijuana’s medical benefits and 39 state attorneys general demand a crackdown on unregulated hemp-derived THC.
Duane Boise, President and CEO of MMJ International Holdings, said that while most of the cannabis industry chased state-based shortcuts, MMJ pursued the hard, federally compliant road – the FDA/DEA drug development pathway – a choice now emerging as the cornerstone of the next era of lawful cannabinoid medicine.
Boise noted that everyone in Washington is talking about cannabis reform, but at MMJ, they are watching the action. He added that the law, the science, and now 39 Attorneys General all point in the same direction: federal control and pharmaceutical compliance.
The Department of Justice’s 2025 concession that the DEA’s internal court system was unconstitutional marked the beginning of a massive federal realignment. Now, the attorneys general from 37 states and two territories have made it explicit that the 2018 Farm Bill’s hemp loophole unleashed an unregulated drug market of “Frankenstein THC” products, endangering children and undermining public health.
These developments signal a federal cannabis reset – one that eliminates gray-market intoxicants and restores legitimate, FDA-supervised research as the only lawful path.
MMJ has spent years building that lawful infrastructure:
- DEA-licensed Schedule I analytical facility (MMJ BioPharma Labs)
- FDA-approved Investigational New Drug (IND) applications
- Orphan Drug Designations for Huntington’s disease and Multiple Sclerosis
- GMP-compliant pharmaceutical softgel capsules for clinical trials
Under a “Federal Control” paradigm, MMJ’s adherence to the FDA-compliant, pharmaceutical pathway transforms from a bureaucratic burden into a competitive superpower.
MMJ’s ongoing constitutional litigation against the DEA has been strengthened by the DOJ’s formal admission that the DEA’s administrative courts were unconstitutional.
A favorable court decision or mandated DEA registration would instantly trigger a valuation surge, advancing R&D and aligning the company with its projected $150-250 million enterprise value under federal market reform scenarios.
The bipartisan letter from 39 Attorneys General calls for criminalizing intoxicating hemp products and redefining hemp to close the Farm Bill loophole. This shift creates an unprecedented divide:
- Illicit operators and hemp ‘chemists’ face extinction under new enforcement.
- Lawful pharmaceutical developers like MMJ gain a level of scarcity and credibility.
MMJ is positioned to emerge as the cornerstone of the federally regulated medical cannabis economy and is structured to have strategic alliances with major pharmaceutical firms, government and VA research contracts, and institutional investment inflows as capital exits noncompliant state markets.
President Trump and DEA Administrator Terry Cole now face a choice – science or stagnation, law or loopholes, reform or relapse.
MMJ International Holdings is a developer of FDA regulated, pharmaceutical grade cannabinoid medicines. MMJ’s subsidiaries, MMJ BioPharma Labs and MMJ BioPharma Cultivation, hold federal designations, DEA licensure, and FDA IND approvals for treating Huntington’s Disease and Multiple Sclerosis. The company has global GMP partnerships supporting clinical manufacturing and data driven cannabinoid therapeutics.
MMJ is represented by attorney Megan Sheehan.
Contact: Madison Hisey, MHisey@mmjih.com, 203-231-85832
Source: MMJ International Holdings
